Recent research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some ...

BeOne Medicines has secured approval from the European Commission (EC) for Tevimbra (tislelizumab) to be used along with ...

Landmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why ...

Libtayo works by attaching itself to a receptor called programmed cell death protein 1 (PD-1) on specific immune system cells called T cells. PD-1 can show up on these cells when cancer has ...

The findings clarify that side effects of cancer treatments may be linked to a specific protein’s critical role in cellular ...

A collaborative study from the University of Cologne has uncovered how a key mitochondrial protein, AIFM1 (Apoptosis-Inducing ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...

As a result, drugs that inhibit MCL-1 can inadvertently damage healthy tissues that rely on this protein for energy, especially in organs with high energy demand like the heart and liver, leading to ...

Scientists at UC Davis discovered a small genetic difference that could explain why humans are more prone to certain cancers ...

The authors noted that there are currently 3 immune-oncologic antibody treatments approved for locally advanced and metastatic cSCCs that target the programmed cell death protein 1/programmed ...

A pioneering discovery at WEHI in 1988 of a protein that stopped programmed cell death sparked huge interest in the field, and has since led to a new drug to treat cancer.